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Background: Melanoma incidence is growing and more people require follow-up to detect recurrent melanoma
quickly. Those detecting their own recurrent melanoma appear to have the best prognosis, so total skin self
examination (TSSE) is advocated, but practice is suboptimal. A digital intervention to support TSSE has potential but
it is not clear which patient groups could benefit most. The aim of this study was to explore cutaneous melanoma
recurrence patterns between 1991 and 2012 in Northeast Scotland. The objectives were to: determine how
recurrent melanomas were detected during the period; explore factors potentially predictive of mode of recurrence
detection; identify groups least likely to detect their own recurrent melanoma and with most potential to benefit
from digital TSSE support.
Methods: Pathology records were used to identify those with a potential recurrent melanoma of any type
(local, regional and distant). Following screening of potential cases available secondary care-held records were
subsequently scrutinised. Data was collected on demographics and clinical characteristics of the initial and recurrent
melanoma. Data were handled in Microsoft Excel and transported into SPSS 20.0 for statistical analysis. Factors
predicting detection at interval or scheduled follow-up were explored using univariate techniques, with potentially
influential factors combined in a multivariate binary logistic model to adjust for confounding.
Results: 149 potential recurrences were identified from the pathology database held at Aberdeen Royal Infirmary.
Reliable data could be obtained on 94 cases of recurrent melanoma of all types. 30 recurrences (31.9%) were found
by doctors at follow-up, and 64 (68.1%) in the interval between visits, usually by the patient themselves. Melanoma
recurrences of all types occurring within one-year were significantly more likely to be found at follow-up visits, and
this remained so following adjustment for other factors that could be used to target digital TSSE support.
Conclusions: A digital intervention should be offered to all newly diagnosed patients. This group could benefit
most from optimal TSSE practice.
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Melanoma incidence has risen over the last 50 years, and
disproportionately affects younger people [1]. Around three
times as many cases were reported in 2000 than in 1970
and it is now the sixth commonest cancer in the UK [2,3].
Scottish guidelines recommend that people treated for cu-
taneous melanoma receive stuctured follow-up consisting* Correspondence: s.hall@abdn.ac.uk
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unless otherwise stated.of regular physical examination by a specialist without
blood tests or imaging unless subsequently indicated [4].
Follow-up aims to detect melanoma recurrences early and
expedite secondary care access if necessary and its delivery
is becoming increasingly burdensome to healthcare systems
[5-7]. Many recurrences are detected in the interval be-
tween structured follow-up visits leading many to question
it value [8,9]. On the other hand there is evidence that most
early recurrences (within two years) are not self-detected
but found at scheduled follow-up appointments [8,10-13].
This is important since there is evidence of superioral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Table 1 Melanoma recurrence data sheet
Surname: DOB:
Forename(s): Gender:
CHI:
Occupation: Ethnicity:
Date of primary melanoma diagnosis:
Melanoma type:
Stage of melanoma:
Tumour thickness (mm): Breslow depth;
Clark level;
Prognostic features: Ulceration;
Lymph node involvement;
Tumour vascularity;
lymphovascular invasion;
Mitotic rate;
Regression;
Microsatellites;
Tumour-infiltrating lymphocytes;
Lactate dehydrogenase serum level;
Tumour anatomical location:
Method/Details of treatment:
Details on how the melanoma was picked up:
Date of excision biopsies: Primary biopsy;
Secondary biopsy;
Punch/Shave biopsy;
Details of prescribed follow-up program:
Date of recurrence diagnosis:
Nature of recurrence: local, regional, distant)
Melanoma type:
Melanoma stage:
Tumour thickness: Breslow depth;
Clark level;
Prognostic features:
Tumour anatomical location:
How was the recurrence detected: Please Tick
Self – detected
GP
Dermatologist
Follow-up appointment
Other
If other, please state:
If self- detected, which of the following apply: Please Tick:
Recurrence found via; Routine self-examination
Accidental find
Aid of partner/Acquaintance
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Table 1 Melanoma recurrence data sheet (Continued)
Experience of related symptoms (e.g. nausea, fatigue,
weight loss, pain, shortness of breath etc.)
Route from self-detection to official diagnosis:
(e.g. Patient – GP – Hospital)
Dates of above referrals: (e.g. GP referral,
treatment dates etc.)
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appear to have superior survival, corresponding with with
findings that regular total skin self examinations (TSSE) in
people treated for primary cutaneous melanoma can re-
duce mortality rates by as much as 63% [13,14].
Despite this TSSE education and practice appear
suboptimal with 70% of American melanoma patients
indicating that they had never been advised to do it [15].
There is good reason to suggest that similar statistics
would be found in North East Scotland (NES). Where
interventions to improve TSSE have been tried, results
have been disappointing and those who were educated by
brochure or video demonstrations only reported increased
TSSE practice for 3–7 months, with overall participation
returning to the baseline by 12 months [16-18]. Despite
this it is encouraging that educational interventions could
achieve 17-50% increases in TSSE practice, albeit in the
short-term. Further, stabilisation of mortality in youn-
ger patients (aged 25–44), despite increasing incidence,
is thought to result from increased public awareness
and TSSE promotion [1,16,19,20]. Similarly higher survival
and higher TSSE rates are observed in less deprived people
[15]. All this supports the view that TSSE is worth doing.
Some suggest that digital interventions could promote
and sustain TSSE practice [18-20]. Such interventions
however, are likely to be expensive to develop and im-
plement so should be targeted at those with the great-
est potential to benefit, information which the current
studies do not provide.
We are developing a digital intervention to promote and
prompt TSSE in Northeast Scotland. We wished to explore
patterns of all types of melanoma recurrence within the
region over recent years to determine when, and to which
patients, this intervention should be targeted.
Methods
Study approval
Formal approval for this study was granted on 10th October
2012 by the Quality, Governance and Risk Unit (Clinical
Effectiveness Team) of NHS Grampian (project ID 2483).
Identifying recurrences
A data-base maintained by the Department of Pathology,
NHS Grampian was scrutinised to identify melanoma
patients from Northeast Scotland potentially diagnosedwith any type of recurrence between August 1992 and
September 2012.
Data collection
A data collection sheet was constructed (Table 1) and used
to abstract data from the secondary care-held medical
records of eligible and available cases at the medical re-
cords department at Aberdeen Royal Infirmary.
The following data were abstracted (Table 2):
i) Demographics: gender; date of birth; age at diagnosis;
age at recurrence; postcode. Postcode was subsequently
use to define deprivation and rurality [21,22].
ii) Clinical details of the initial melanoma including:
melanoma type; Breslow thickness; anatomical
location.
iii)Type of recurrence: local; regional; distant.
iv) Recurrence pathway: time to recurrence; mode of
detection (self detected and reported during interval;
found at follow-up clinic by clinician; emergency
admission during interval; other).
Data were entered handled using a Microsoft Excel
worksheet. After scrutiny for errors they were read into
SPSS version 20 for further statistical analysis.
Statistical analysis
Demographic and clinical characteristics
Basic descriptive statistics of the sample were prepared.
Demographics characteristics, clinical characteristics of the
primary melanoma and details of the recurrence and its
detection pathway were explored.
Categorising variables
To conduct meaningful univariate analysis on this relatively
small sample was challenging. A number of categorical
variables were created from the data to address this.
After discussion amongst the authors a binary outcome
variable was created distinguishing those patients who
had their recurrent melanoma detected de-novo at the
follow-up clinic versus those in whom the presentation
of recurrence had occurred in the interval between
scheduled follow-up visits. Arguably, the former group
are those who stand most to gain from interventions to
promote total skin self examination.
Table 2 Clinicopathological Characteristics; descriptive
statistics in relation to frequency within sample of
94 patients
Frequency:
Demographics:
Gender;
Female 37 (39.4%)
Male 57 (60.6%)
Deprivation score;
1(most deprived) 5 (5.3%)
2 9 (9.6%)
3 22 (23.4%)
4 27 (28.7%)
5(least deprived) 31 (33.0%)
Six-fold rurality score;
Urban 43 (45.6%)
Rural 51 (54.4%)
Type of recurrence
Local 21 (22.3%)
Regional 48 (51.1%)
Distant 25 (26.6%)
Details of first primary:
Age at diagnosis;
<=50 years 19 (20.2%)
51-70 years 41 (43.6%)
71+ years 33 (35.1%)
Unknown 1 (1.1%)
Melanoma type of first primary;
Superficial spreading 27 (28.7%)
Nodular malignant 30 (31.9%)
Lentigo maligna 5 (5.3%)
Acral lentiginous 5 (5.3%)
Other 27 (28.7%)
Location of first primary;
Lower limbs 35 (37.2%)
Trunk 20 (21.3%)
Upper limbs 9 (9.6%)
Head and neck 22 (23.4%)
Mucus membranes 4 (4.3%)
Eye 4 (4.3%)
Breslow thickness of first primary;
<0.75 mm 1 (1.1%)
0.76-4.00 mm 18 (19.1%)
>4.00 mm 36 (38.3%)
Unknown 27 (28.7%)
12 (12.8%)
Table 2 Clinicopathological Characteristics; descriptive
statistics in relation to frequency within sample of
94 patients (Continued)
Details of recurrence:
Age at recurrence;
<=50 years 14 (14.9%)
51-70 years 40 (42.6%)
71+ years 40 (42.6%)
Time to recurrence;
0-12 months 27 (28.7%)
13-24 months 28 (29.8%)
25-36 11 (11.7%)
37-48 5 (5.3%)
49-60 7 (7.4%)
5+ years 15 (16.0%)
Unknown 1 (1.1%)
How recurrence was detected;
Self-detected and reported during interval 45 (48.9%)
New finding at follow-up clinical 30 (31.9%)
Emergency admission with symptoms in interval 11 (11.7%)
Other 5 (5.3%)
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were selected on the basis that there was evidence for,
or it seemed plausible that, they could be influential on
whether recurrent melanoma was detected at scheduled
follow-up or during the interval between scheduled
follow-up appointments. Candidates were classified by
gender, 5-fold deprivation score and 2-fold rurality score.
With reference to recurrent melanoma, variables including
age (<65 versus ≥65 years) time to recurrence (< 1 year ver-
sus ≥ 1 year) were considered and details of the initial mel-
anoma (subtype, Breslow thickness (<4 mm; ≥4 mm)) [8].
Univariate analysis
The outcome variable (detected at scheduled follow-up
or not) was cross-tabulated with each of the six predictor
variables. The chi-squared test was used to ascertain if the
six factors were significantly associated with follow-up
versus interval detection, with statistical significance
being designated as a p ≤ 0.05. The strength of the relation-
ship between the outcome and each of the six predictor
variables was also explored univariately using binary logistic
regression to generate odds ratios and 95% CIs.
Multivariate analysis
A multivariate binary logistic regression model was then
constructed including all factors found to be significantly
predictive of follow-up versus interval recurrence detec-
tion, as well as those factors that could conceivably
inform targeting of a digital intervention to support
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recurrence; rurality; deprivation score).
Results
Included and excluded cases
149 potential cases of any type of recurrent melanoma
were identified (Figure 1). Eighteen people had died and
notes were not available and four sets of notes could not
be located. Thirty-one people had recurrent melanoma
with no record of a prior primary. Two further apparent
recurrences proved to be new basal cell carcinomas on
review of pathology data. This resulted in 55 exclusions
and a final sample of 94 cases for analysis.
Demographic and clinical characteristics
Demographics and characteristics of primary melanomas
are shown in Table 2. The sample included 21 (22.3%) local,
48 (51.1%) regional and 25 (26.6%) distant recurrences.
Mean age at the time of recurrence was 65 years. Forty-five
recurrences (58.5%) had presented within two years of
diagnosis. Thirty (31.9%) cases were detected at sched-
uled melanoma follow-up appointments. The remaining
64 (69.1%) were detected as interval events with 45
(48.9%) being obviously self detected, 11 (11.7%) being
emergency admissions to hospital with metastatic disease
and five (5.3%) being detected through another route,
mostly incidental findings.
Univariate analysis
Those variables deemed most likely to affect whether a
recurrence was found at follow-up or self detected in the
interval were explored univariately with the chi-squared
test (Table 3). The most striking finding was earlier recur-
rences were significantly more to be detected at structured149 cases of potential 
recurrence or identified 
from Pathology data
4 ca
fu
94 cases with 
supported notes
18 cases dead
94 suitable cases 
found for date 
collection
SCI S
Figure 1 Study flow.follow-up. Of recurrences within a year of diagnosis 51.9%
were detected at follow-up, while only 23.9% of later
recurrences were detected at follow-up. No other po-
tential predictors of recurrence detection location were
significant univariately.
Logistic regression
A binary logistic regression of mode of recurrence detec-
tion (at follow-up versus interval) was conducted (Table 4).
Those who had a recurrence within one year were 3.433
(95% CIs 1.340-8.796) times more likely to be detected at
structured follow up than in the interval. Following adjust-
ment for other potential explanatory variables time to re-
currence remained the only potentially explanatory variable
significantly associated with mode of recurrence detection
(OR2.891 (95% CIs 1.082-7.720).
Discussion
Summary of key findings
Approximately one-third of recurrent melanomas in this
small sample were detected at a routine scheduled follow-
up appointment. Of those presenting in the interval, the
majority were detected by the patient themselves. Of poten-
tial predictors of mode of melanoma recurrence only time
to recurrence was statistically significant, with people being
much less likely to detect their own recurrence within the
first year since diagnosis.
Context with other literature
In this sample nearly one third of melanoma recurrences
were detected at scheduled follow-up appointments. This
accords with previous findings that 26-45% of melanoma
recurrences are found at scheduled follow-up by a clin-
ician [8,9,13]. Of the remaining two thirds the majorityses could not be
rther identified
145 patients
2 cases of Basal Cell 
Carcinoma
31 cases of recurrence 
only
tore consulted for
Table 3 Cross tab data analysis; determining the
significance of categorised variables on likelihood to
present at follow-up or in interval
Descriptive statistic: Detected at
follow-up:
Detected
in interval:
p. value:
Gender; .413
Female 8 (21.6%) 29 (78.4%)
Male 15 (26.3%)′ 42 (73.7%)
Deprivation score; .341
1(most deprived) 3 (60.0%) 2 (40.0%)
2 3 (33.3%) 6 (66.7%)
3 6 (27.3%) 16 (72.7%)
4 7 (25.9%) 20 (74.15)
5(least deprived) 4 (12.9%) 27 (87.1%)
Rurality; .571
Urban 14 (32.6%) 29 (67.4%)
Rural 9 (17.6%) 42 (82.4%)
Melanoma type; .964
Superficial spreading 7 (25.9%) 20 (74.1%)
Nodular malignant 8 (26.7%) 22 (73.3%)
Lentigo maligna 1 (20.0%) 4 (80.0%)
Acral lentiginous 1 (20.0% 4 (80.0%)
Other 6 (22.2%) 21 (77.8%)
Breslow thickness; .252
4 mm or less 11 (20.0%) 44 (80.0%)
>4 mm 12 (30.8%) 27 (69.2%)
Age at Dx; .142
Up to 65 years 12 (25.0%) 36 (75%)
65 years and above 18 (39.1%) 28 (60.9%)
Time to recurrence; .008
12 months or less 14 (51.9%) 13 (48.1%)
Beyond 12 months 16 (23.9%) 51 (76.2%)
Table 4 Binary logistic regression; odds ratio of having
recurrence detected at routine follow-up versus interval,
based on key variables and individual factors
Odds
ratio:
95% CI for odds ratio:
Lower Upper
Time to recurrence (< 1 year) 3.433 1.340 8.796
Gender (male) 1.295 .486 3.449
Age (>65 years) 1.351 .518 3.523
Melanoma type
(Nodular vs. superficial) .842 .274 2.586
(Lentigo vs. superficial) .632 .088 4.532
(Acral vs. superficial) 1.684 .162 17.516
(Other vs. superficial) .842 .267 2.660
Breslow thickness (Thicker (>4 mm)) 1.667 .694 4.004
Rurality (Urban) 1.286 .539 3.067
Deprivation (Deprived) 1.750 .548 5.591
Adjusted binary logistic regression:
Time to recurrence 2.891 1.082 7.720
Age 1.714 .666 4.415
Breslow thickness 1.443 .573 3.635
Rurality 1.377 .527 3.596
Deprivation 1.626 .454 5.816
Adjusted Binary Logistic Regression; adjusted for variables we deemed could
influence our values.
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between follow-up visits. Again, this accords with previous
findings which report that between 47-68% of recurrent
melanomas are self-detected [8,9]. That almost two thirds
of people in this sample, and similar proportions in previ-
ous studies, have detected their own recurrence supports
the view expressed by some that the resources devoted to
melanoma follow-up should be used to educate patients
in the practice of TSSE, rather than being spent on blood
tests and clinical imaging [8-10,12,23,24]. The 16 patients
with emergency or incidental presentation of their melan-
oma might all represent missed opportunities to self-detect
recurrent melanoma with effective TSSE. A digital method
to prompting and support TSSE appears timely and
warranted [13,14]. Implementing novel technological
approaches to cancer can be costly [25]. Our data suggestthis cost could be mitigated by targeting those most likely
to benefit.
Previous researchers have established that adjusting to
a diagnosis of cancer takes time [26]. It is striking that
those within a year of diagnosis were less likely to detect
their own recurrent melanoma. This finding fits well with
the notion of taking time to adjust to melanoma and the
practice of TSSE [27]. Perhaps those in the immediate
post-diagnostic period have most to gain from intensive
support with respect to TSSE. In this context it is reassur-
ing to note that previous interventions to promote TSSE,
demonstrate it can be increased by well designed educa-
tional interventions [17-20].
Strengths and limitations
Our study contributes knowledge to an under-researched
area, the epidemiology of recurrent melanoma. Our study
was rigorous and based on high quality clinical databases
and medical records. This was not an attempt to fully
describe the epidemiology of recurrent melanoma in
Northeast Scotland. Instead the authors were able to
conduct a pragmatic study which provided invaluable
information to inform the further development of a digital
intervention to support TSSE in those diagnosed with cuta-
neous melanoma. The results are broadly in keeping with
what has been published on melanoma recurrence before,
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vention should be targeted to achieve maximum benefit in
a way that previous research has not done.
This sample of patients was small from a relatively
small area. The results may not be generalizable. How-
ever, two facts mitigate against this limitation. Firstly, in
population terms melanoma recurrence is relatively rare
and consequently its epidemiology is under-researched.
Small studies such as this can signpost the way toward
much needed larger studies. Secondly, proportions of
follow-up versus self detected melanoma observed here
are similar to those previously reported from other re-
gions. This suggests that there is scope for others to
add to our findings using similar small samples. A fur-
ther related limitation is that the sample is dominated
by men. Since men are arguably less likely to sustain
TSSE this should be borne in mind as a potential con-
founder for which we have not been adequately able to
control. As with all retrospective studies based upon
medical records this study was limited by the availabil-
ity and quality of records. This limitation is, however,
common to almost all previous work on the epidemi-
ology of recurrent melanoma, further highlighting the
need for larger studies on the epidemiology of melanoma
recurrence in future.Conclusions
Scheduled follow-up is important and effective in detecting
recurrent melanoma particularly in the immediate post
diagnostic period. Patients who are within one year of
being diagnosed with a primary cutaneous melanoma
are significantly less likely to detect their own recurrence,
potentially placing them at risk of poorer outcomes. A
digital intervention to prompt and support TSSE for
people diagnosed with cutaneous melanoma should
start immediately a patient enters follow-up. Such an
intervention should not be viewed as an alternative to
current structured follow-up and may become less ne-
cessary over time. An immediate research priority is to
develop an effective and user friendly digital applica-
tion to prompt and support TSSE in those newly diag-
nosed with cutaneous melanoma. Subsequent research
should include a randomised trial to ensure that such
an intervention can sustain TSSE in the longer term.
Further large-scale research on the epidemiology of re-
current melanoma is also required.
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